Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 7Nivolumab 3atezolizumab 2Aminolevulinic Acid 2testosterone enanthate 1regorafenib 1osimertinib 1nanocis 1fluoroazomycin arabinoside 1fludarabine 1cobimetinib 1cabozantinib 1avelumab 1aldesleukin 1aflibercept 1Vorinostat 1Therapeutics 1Technetium-99 1Solutions 1Red Light 1Radiation, Ionizing 1Proton Pump Inhibitors 1Paclitaxel 1Observation 1NEO212 1Metformin 1Ipilimumab 1Interleukin-2 1Infracyanine green 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × nanocis × Gynecologic × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡